Zopiclone

Biotrade Recommends Consumers Stop Consumption of U-Dream Product Immediately

Retrieved on: 
Friday, December 20, 2019

VICTORIA, Dec. 20, 2019 /CNW/ - On December 17th, Health Canada formally indicated that they have found "Zopicloneimpurity22" in some batches of the U-Dream product.

Key Points: 
  • VICTORIA, Dec. 20, 2019 /CNW/ - On December 17th, Health Canada formally indicated that they have found "Zopicloneimpurity22" in some batches of the U-Dream product.
  • Health Canada has confirmed that Zopiclone is not present in the product.
  • As Health Canada has not given any indication regarding the amounts of the impurity detected, Biotrade recommends consumers stop using U-Dream products.
  • As of November 21st, based on an initial concern raised by Health Canada, Biotrade Canada immediately stopped distribution and informed retailers to pull the product from store shelves and to stop selling.

FDA requires stronger warnings about rare but serious incidents related to certain prescription insomnia medicines

Retrieved on: 
Tuesday, April 30, 2019

The boxed warning follows several reports of rare, but serious injuries and deaths resulting from various complex sleep behaviors after taking these medicines.

Key Points: 
  • The boxed warning follows several reports of rare, but serious injuries and deaths resulting from various complex sleep behaviors after taking these medicines.
  • The new warnings will be required for eszopiclone (Lunesta), zaleplon (Sonata) and zolpidem (Ambien, Ambien CR, Edluar, Intermezzo, and Zolpimist).
  • "We recognize that millions of Americans suffer from insomnia and rely on these drugs to help them sleep better at night.
  • While these incidents are rare, they are serious and it's important that patients and health care professionals are aware of the risk.